Share Price and Basic Stock Data
Last Updated: December 5, 2025, 6:32 pm
| PEG Ratio | -1.03 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Kwality Pharmaceuticals Ltd operates within the pharmaceuticals sector, with a current market capitalization of ₹934 Cr. The company’s stock is priced at ₹900, reflecting a price-to-earnings (P/E) ratio of 19.0. Over the years, Kwality has demonstrated fluctuating revenue performance. For instance, sales rose from ₹60 Cr in March 2014 to ₹456 Cr in March 2022, marking a significant growth trajectory. However, sales declined to ₹251 Cr in March 2023 before bouncing back to ₹307 Cr in March 2024 and reaching ₹370 Cr in March 2025. This indicates a recovery phase, particularly with trailing twelve-month (TTM) sales recorded at ₹402 Cr. Quarterly sales have also shown variability, with the most recent quarter ending September 2023 recording sales of ₹70 Cr, and projections for December 2023 at ₹78 Cr. Such trends indicate that while the company faces challenges, it is gradually regaining momentum in revenue generation.
Profitability and Efficiency Metrics
Kwality Pharmaceuticals has reported varying profitability metrics, with a net profit of ₹43 Cr and a net profit margin of 10.75% for the year ending March 2025. The return on equity (ROE) stood at 16.2%, while the return on capital employed (ROCE) was recorded at 18.2%. The operating profit margin (OPM) has shown resilience, maintaining around 22% in recent quarters, reflecting effective cost management despite fluctuating sales. Additionally, the interest coverage ratio (ICR) of 8.33x indicates that the company can comfortably meet its interest obligations. However, the cash conversion cycle (CCC) remains elevated at 209 days, which may affect liquidity and operational efficiency. The company’s ability to improve its OPM while managing expenses will be critical in bolstering profitability in the competitive pharmaceutical landscape.
Balance Sheet Strength and Financial Ratios
Kwality Pharmaceuticals’ balance sheet reveals a total asset base of ₹451 Cr as of March 2025, with total liabilities amounting to ₹451 Cr, reflecting a balanced financial structure. The company reported reserves of ₹282 Cr against borrowings of ₹110 Cr, indicating a healthy equity position. The debt-to-equity ratio stands at 0.42, suggesting a moderate level of leverage. Key financial ratios indicate a strong performance, with a current ratio of 1.67 and a quick ratio of 1.18, both suggesting adequate short-term liquidity. The book value per share increased to ₹254.47 in March 2025, further underscoring the company’s financial health. However, the inventory turnover ratio of 4.57x indicates some inefficiencies in stock management. Overall, Kwality’s financial ratios reflect a solid foundation, albeit with areas for operational improvement.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Kwality Pharmaceuticals indicates a stable promoter holding of 54.82%, which is a positive sign for investor confidence. The public holds 44.83% of shares, while foreign institutional investors (FIIs) have not participated, and domestic institutional investors (DIIs) account for a mere 0.33%. This distribution suggests a reliance on retail investors, which may introduce volatility. The number of shareholders has grown significantly, from 5,376 in December 2022 to 11,595 by September 2025, indicating increasing interest in the company. However, the low institutional involvement may limit the stock’s stability and growth potential. The gradual increase in DII holdings could signify growing institutional confidence in the company’s long-term prospects, but continued monitoring is essential.
Outlook, Risks, and Final Insight
Looking ahead, Kwality Pharmaceuticals faces both opportunities and challenges. The recovery in sales and profitability metrics suggests a positive trajectory, but the company must address operational inefficiencies, particularly concerning its cash conversion cycle and inventory management. Risks include reliance on a limited investor base and potential fluctuations in raw material costs, which could impact profitability. The pharmaceutical sector is also experiencing increasing competition, necessitating innovation and efficiency to maintain market share. If the company can enhance its operational efficiency and attract more institutional investors, it may strengthen its market position. Conversely, failure to manage costs effectively or adapt to market changes could hinder growth. Continuous focus on improving margins and operational metrics will be crucial for sustaining investor confidence and driving long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Kwality Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 247/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,110 Cr. | 377 | 479/192 | 85.1 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.0 | 30.5/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,585.18 Cr | 1,173.27 | 52.01 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70 | 56 | 56 | 69 | 67 | 70 | 78 | 92 | 80 | 90 | 84 | 116 | 111 |
| Expenses | 52 | 40 | 41 | 57 | 54 | 54 | 61 | 71 | 63 | 70 | 67 | 90 | 87 |
| Operating Profit | 18 | 16 | 15 | 12 | 14 | 15 | 17 | 21 | 17 | 20 | 18 | 26 | 24 |
| OPM % | 26% | 28% | 27% | 17% | 20% | 22% | 21% | 23% | 22% | 22% | 21% | 22% | 22% |
| Other Income | 0 | 1 | 0 | -15 | 0 | 0 | 1 | -7 | 0 | 0 | 1 | 1 | 0 |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 3 |
| Depreciation | 3 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 |
| Profit before tax | 14 | 11 | 10 | -10 | 7 | 8 | 10 | 6 | 11 | 13 | 11 | 19 | 17 |
| Tax % | 25% | 20% | 28% | -24% | 25% | 24% | 21% | 28% | 25% | 33% | 25% | 24% | 30% |
| Net Profit | 11 | 9 | 7 | -7 | 5 | 6 | 8 | 4 | 8 | 8 | 9 | 14 | 12 |
| EPS in Rs | 10.17 | 8.72 | 6.97 | -7.09 | 5.25 | 6.03 | 7.42 | 4.34 | 8.07 | 8.18 | 8.23 | 13.97 | 11.50 |
Last Updated: August 20, 2025, 7:55 am
Below is a detailed analysis of the quarterly data for Kwality Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 111.00 Cr.. The value appears to be declining and may need further review. It has decreased from 116.00 Cr. (Mar 2025) to 111.00 Cr., marking a decrease of 5.00 Cr..
- For Expenses, as of Jun 2025, the value is 87.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 90.00 Cr. (Mar 2025) to 87.00 Cr., marking a decrease of 3.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 2.00 Cr..
- For OPM %, as of Jun 2025, the value is 22.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 22.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 17.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 17.00 Cr., marking a decrease of 2.00 Cr..
- For Tax %, as of Jun 2025, the value is 30.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Mar 2025) to 30.00%, marking an increase of 6.00%.
- For Net Profit, as of Jun 2025, the value is 12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Mar 2025) to 12.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 11.50. The value appears to be declining and may need further review. It has decreased from 13.97 (Mar 2025) to 11.50, marking a decrease of 2.47.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:58 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 52 | 76 | 95 | 137 | 165 | 138 | 261 | 456 | 251 | 307 | 370 | 402 |
| Expenses | 56 | 49 | 70 | 86 | 125 | 149 | 124 | 231 | 284 | 190 | 241 | 290 | 314 |
| Operating Profit | 4 | 4 | 6 | 9 | 12 | 15 | 14 | 29 | 172 | 61 | 67 | 80 | 87 |
| OPM % | 6% | 7% | 8% | 9% | 8% | 9% | 10% | 11% | 38% | 24% | 22% | 22% | 22% |
| Other Income | 0 | 1 | 0 | 2 | 1 | 1 | 4 | 2 | 4 | -14 | -5 | 2 | 2 |
| Interest | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 7 | 10 | 10 | 10 |
| Depreciation | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 6 | 11 | 15 | 20 | 18 | 19 |
| Profit before tax | 2 | 2 | 3 | 6 | 8 | 11 | 11 | 22 | 162 | 26 | 31 | 54 | 60 |
| Tax % | 47% | 29% | 39% | 41% | 38% | 31% | 24% | 29% | 26% | 24% | 24% | 26% | |
| Net Profit | 1 | 1 | 2 | 3 | 5 | 8 | 8 | 15 | 120 | 19 | 24 | 40 | 43 |
| EPS in Rs | 0.95 | 1.32 | 1.89 | 3.31 | 4.51 | 7.28 | 8.12 | 14.86 | 115.70 | 18.76 | 23.11 | 38.44 | 41.88 |
| Dividend Payout % | 0% | 0% | 0% | 9% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 100.00% | 50.00% | 66.67% | 60.00% | 0.00% | 87.50% | 700.00% | -84.17% | 26.32% | 66.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | 100.00% | -50.00% | 16.67% | -6.67% | -60.00% | 87.50% | 612.50% | -784.17% | 110.48% | 40.35% |
Kwality Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 22% |
| 3 Years: | -7% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 41% |
| 5 Years: | 37% |
| 3 Years: | -31% |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 73% |
| 3 Years: | 34% |
| 1 Year: | 19% |
| Return on Equity | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 28% |
| 3 Years: | 15% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 9:25 am
Balance Sheet
Last Updated: December 4, 2025, 1:33 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 13 | 15 | 18 | 21 | 21 | 28 | 37 | 52 | 172 | 192 | 216 | 255 | 282 |
| Borrowings | 6 | 8 | 13 | 19 | 26 | 28 | 35 | 41 | 54 | 90 | 98 | 112 | 110 |
| Other Liabilities | 12 | 10 | 17 | 27 | 41 | 40 | 53 | 65 | 106 | 71 | 74 | 72 | 79 |
| Total Liabilities | 35 | 38 | 52 | 72 | 98 | 107 | 135 | 169 | 343 | 364 | 398 | 451 | 481 |
| Fixed Assets | 11 | 11 | 11 | 16 | 19 | 28 | 42 | 56 | 91 | 120 | 138 | 144 | 143 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 12 | 14 | 0 | 0 | 0 |
| Investments | 3 | 4 | 5 | 7 | 9 | 8 | 8 | 9 | 4 | 4 | 4 | 4 | 4 |
| Other Assets | 21 | 23 | 36 | 50 | 70 | 71 | 86 | 102 | 236 | 226 | 256 | 303 | 335 |
| Total Assets | 35 | 38 | 52 | 72 | 98 | 107 | 135 | 169 | 343 | 364 | 398 | 451 | 481 |
Below is a detailed analysis of the balance sheet data for Kwality Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 282.00 Cr.. The value appears strong and on an upward trend. It has increased from 255.00 Cr. (Mar 2025) to 282.00 Cr., marking an increase of 27.00 Cr..
- For Borrowings, as of Sep 2025, the value is 110.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 112.00 Cr. (Mar 2025) to 110.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 79.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 72.00 Cr. (Mar 2025) to 79.00 Cr., marking an increase of 7.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 481.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 451.00 Cr. (Mar 2025) to 481.00 Cr., marking an increase of 30.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 143.00 Cr.. The value appears to be declining and may need further review. It has decreased from 144.00 Cr. (Mar 2025) to 143.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
- For Other Assets, as of Sep 2025, the value is 335.00 Cr.. The value appears strong and on an upward trend. It has increased from 303.00 Cr. (Mar 2025) to 335.00 Cr., marking an increase of 32.00 Cr..
- For Total Assets, as of Sep 2025, the value is 481.00 Cr.. The value appears strong and on an upward trend. It has increased from 451.00 Cr. (Mar 2025) to 481.00 Cr., marking an increase of 30.00 Cr..
Notably, the Reserves (282.00 Cr.) exceed the Borrowings (110.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.00 | -4.00 | -7.00 | -10.00 | -14.00 | -13.00 | -21.00 | -12.00 | 118.00 | -29.00 | -31.00 | -32.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 41 | 63 | 95 | 87 | 99 | 86 | 80 | 53 | 57 | 107 | 138 | 154 |
| Inventory Days | 58 | 61 | 54 | 72 | 54 | 34 | 94 | 38 | 97 | 310 | 187 | 167 |
| Days Payable | 58 | 40 | 61 | 67 | 79 | 52 | 96 | 58 | 63 | 117 | 106 | 112 |
| Cash Conversion Cycle | 41 | 85 | 89 | 92 | 74 | 68 | 78 | 33 | 91 | 300 | 219 | 209 |
| Working Capital Days | 60 | 35 | 41 | 21 | 19 | 21 | 43 | 25 | 62 | 120 | 103 | 100 |
| ROCE % | 12% | 11% | 15% | 19% | 19% | 21% | 18% | 26% | 97% | 18% | 16% | 18% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 38.36 | 22.76 | 18.16 | 115.64 | 14.60 |
| Diluted EPS (Rs.) | 38.36 | 22.76 | 18.16 | 115.64 | 14.60 |
| Cash EPS (Rs.) | 55.99 | 41.61 | 33.00 | 125.89 | 20.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 253.70 | 213.74 | 191.08 | 172.50 | 56.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 254.47 | 214.51 | 191.85 | 173.27 | 57.68 |
| Revenue From Operations / Share (Rs.) | 356.77 | 296.03 | 241.93 | 439.64 | 252.51 |
| PBDIT / Share (Rs.) | 79.32 | 65.67 | 60.79 | 168.82 | 29.33 |
| PBIT / Share (Rs.) | 61.70 | 46.82 | 46.38 | 158.52 | 23.07 |
| PBT / Share (Rs.) | 52.18 | 29.97 | 24.65 | 155.71 | 20.50 |
| Net Profit / Share (Rs.) | 38.36 | 22.76 | 18.58 | 115.59 | 14.35 |
| NP After MI And SOA / Share (Rs.) | 38.40 | 22.93 | 18.67 | 115.64 | 14.60 |
| PBDIT Margin (%) | 22.23 | 22.18 | 25.12 | 38.39 | 11.61 |
| PBIT Margin (%) | 17.29 | 15.81 | 19.16 | 36.05 | 9.13 |
| PBT Margin (%) | 14.62 | 10.12 | 10.18 | 35.41 | 8.11 |
| Net Profit Margin (%) | 10.75 | 7.68 | 7.68 | 26.29 | 5.68 |
| NP After MI And SOA Margin (%) | 10.76 | 7.74 | 7.71 | 26.30 | 5.78 |
| Return on Networth / Equity (%) | 15.13 | 10.65 | 9.69 | 66.53 | 25.09 |
| Return on Capital Employeed (%) | 23.04 | 20.04 | 21.13 | 78.21 | 27.21 |
| Return On Assets (%) | 8.90 | 6.03 | 5.47 | 35.23 | 9.10 |
| Long Term Debt / Equity (X) | 0.05 | 0.08 | 0.13 | 0.11 | 0.30 |
| Total Debt / Equity (X) | 0.42 | 0.43 | 0.45 | 0.24 | 0.57 |
| Asset Turnover Ratio (%) | 0.87 | 0.82 | 0.72 | 1.79 | 1.73 |
| Current Ratio (X) | 1.67 | 1.60 | 1.65 | 1.75 | 1.35 |
| Quick Ratio (X) | 1.18 | 1.08 | 0.95 | 1.34 | 1.13 |
| Inventory Turnover Ratio (X) | 4.57 | 1.87 | 1.62 | 5.64 | 8.31 |
| Interest Coverage Ratio (X) | 8.33 | 6.56 | 10.48 | 60.05 | 11.39 |
| Interest Coverage Ratio (Post Tax) (X) | 5.03 | 3.96 | 6.95 | 42.11 | 6.57 |
| Enterprise Value (Cr.) | 997.78 | 515.35 | 400.57 | 630.81 | 85.72 |
| EV / Net Operating Revenue (X) | 2.70 | 1.68 | 1.60 | 1.38 | 0.32 |
| EV / EBITDA (X) | 12.12 | 7.56 | 6.35 | 3.60 | 2.82 |
| MarketCap / Net Operating Revenue (X) | 2.44 | 1.38 | 1.27 | 1.32 | 0.22 |
| Price / BV (X) | 3.43 | 1.90 | 1.60 | 3.34 | 0.96 |
| Price / Net Operating Revenue (X) | 2.44 | 1.38 | 1.27 | 1.32 | 0.22 |
| EarningsYield | 0.04 | 0.05 | 0.06 | 0.19 | 0.26 |
After reviewing the key financial ratios for Kwality Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 38.36. This value is within the healthy range. It has increased from 22.76 (Mar 24) to 38.36, marking an increase of 15.60.
- For Diluted EPS (Rs.), as of Mar 25, the value is 38.36. This value is within the healthy range. It has increased from 22.76 (Mar 24) to 38.36, marking an increase of 15.60.
- For Cash EPS (Rs.), as of Mar 25, the value is 55.99. This value is within the healthy range. It has increased from 41.61 (Mar 24) to 55.99, marking an increase of 14.38.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 253.70. It has increased from 213.74 (Mar 24) to 253.70, marking an increase of 39.96.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 254.47. It has increased from 214.51 (Mar 24) to 254.47, marking an increase of 39.96.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 356.77. It has increased from 296.03 (Mar 24) to 356.77, marking an increase of 60.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 79.32. This value is within the healthy range. It has increased from 65.67 (Mar 24) to 79.32, marking an increase of 13.65.
- For PBIT / Share (Rs.), as of Mar 25, the value is 61.70. This value is within the healthy range. It has increased from 46.82 (Mar 24) to 61.70, marking an increase of 14.88.
- For PBT / Share (Rs.), as of Mar 25, the value is 52.18. This value is within the healthy range. It has increased from 29.97 (Mar 24) to 52.18, marking an increase of 22.21.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 38.36. This value is within the healthy range. It has increased from 22.76 (Mar 24) to 38.36, marking an increase of 15.60.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 38.40. This value is within the healthy range. It has increased from 22.93 (Mar 24) to 38.40, marking an increase of 15.47.
- For PBDIT Margin (%), as of Mar 25, the value is 22.23. This value is within the healthy range. It has increased from 22.18 (Mar 24) to 22.23, marking an increase of 0.05.
- For PBIT Margin (%), as of Mar 25, the value is 17.29. This value is within the healthy range. It has increased from 15.81 (Mar 24) to 17.29, marking an increase of 1.48.
- For PBT Margin (%), as of Mar 25, the value is 14.62. This value is within the healthy range. It has increased from 10.12 (Mar 24) to 14.62, marking an increase of 4.50.
- For Net Profit Margin (%), as of Mar 25, the value is 10.75. This value exceeds the healthy maximum of 10. It has increased from 7.68 (Mar 24) to 10.75, marking an increase of 3.07.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.76. This value is within the healthy range. It has increased from 7.74 (Mar 24) to 10.76, marking an increase of 3.02.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.13. This value is within the healthy range. It has increased from 10.65 (Mar 24) to 15.13, marking an increase of 4.48.
- For Return on Capital Employeed (%), as of Mar 25, the value is 23.04. This value is within the healthy range. It has increased from 20.04 (Mar 24) to 23.04, marking an increase of 3.00.
- For Return On Assets (%), as of Mar 25, the value is 8.90. This value is within the healthy range. It has increased from 6.03 (Mar 24) to 8.90, marking an increase of 2.87.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has decreased from 0.08 (Mar 24) to 0.05, marking a decrease of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.43 (Mar 24) to 0.42, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has increased from 0.82 (Mar 24) to 0.87, marking an increase of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.67. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 1.67, marking an increase of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has increased from 1.08 (Mar 24) to 1.18, marking an increase of 0.10.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.57. This value is within the healthy range. It has increased from 1.87 (Mar 24) to 4.57, marking an increase of 2.70.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.33. This value is within the healthy range. It has increased from 6.56 (Mar 24) to 8.33, marking an increase of 1.77.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.03. This value is within the healthy range. It has increased from 3.96 (Mar 24) to 5.03, marking an increase of 1.07.
- For Enterprise Value (Cr.), as of Mar 25, the value is 997.78. It has increased from 515.35 (Mar 24) to 997.78, marking an increase of 482.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.70. This value is within the healthy range. It has increased from 1.68 (Mar 24) to 2.70, marking an increase of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is 12.12. This value is within the healthy range. It has increased from 7.56 (Mar 24) to 12.12, marking an increase of 4.56.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.44. This value is within the healthy range. It has increased from 1.38 (Mar 24) to 2.44, marking an increase of 1.06.
- For Price / BV (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has increased from 1.90 (Mar 24) to 3.43, marking an increase of 1.53.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.44. This value is within the healthy range. It has increased from 1.38 (Mar 24) to 2.44, marking an increase of 1.06.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kwality Pharmaceuticals Ltd:
- Net Profit Margin: 10.75%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.04% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.13% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.03
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.18
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 19 (Industry average Stock P/E: 52.01)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.42
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.75%
Fundamental Analysis of Kwality Pharmaceuticals Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village Nagkalan, Amritsar Punjab 143601 | cs@kwalitypharma.com http://www.kwalitypharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ramesh Arora | Managing Director |
| Mr. Aditya Arora | WholeTime Director & CFO |
| Mr. Ajay Kumar Arora | Whole Time Director |
| Mrs. Anju Arora | Whole Time Director |
| Mrs. Geeta Arora | Whole Time Director |
| Mr. Kiran Kumar Verma | Independent Director |
| Mr. Pankaj Takkar | Independent Director |
| Mr. Prashanth Vellanki | Independent Director |
| Mr. Ravi Shanker Singh | Independent Director |
| Mr. Kartik Kapur | Independent Director |
Kwality Pharmaceuticals Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹504.25 |
| Previous Day | ₹507.10 |
FAQ
What is the intrinsic value of Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd's intrinsic value (as of 05 December 2025) is 705.77 which is 21.58% lower the current market price of 900.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 934 Cr. market cap, FY2025-2026 high/low of 1,235/596, reserves of ₹282 Cr, and liabilities of 481 Cr.
What is the Market Cap of Kwality Pharmaceuticals Ltd?
The Market Cap of Kwality Pharmaceuticals Ltd is 934 Cr..
What is the current Stock Price of Kwality Pharmaceuticals Ltd as on 05 December 2025?
The current stock price of Kwality Pharmaceuticals Ltd as on 05 December 2025 is 900.
What is the High / Low of Kwality Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kwality Pharmaceuticals Ltd stocks is 1,235/596.
What is the Stock P/E of Kwality Pharmaceuticals Ltd?
The Stock P/E of Kwality Pharmaceuticals Ltd is 19.0.
What is the Book Value of Kwality Pharmaceuticals Ltd?
The Book Value of Kwality Pharmaceuticals Ltd is 281.
What is the Dividend Yield of Kwality Pharmaceuticals Ltd?
The Dividend Yield of Kwality Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Kwality Pharmaceuticals Ltd?
The ROCE of Kwality Pharmaceuticals Ltd is 18.2 %.
What is the ROE of Kwality Pharmaceuticals Ltd?
The ROE of Kwality Pharmaceuticals Ltd is 16.2 %.
What is the Face Value of Kwality Pharmaceuticals Ltd?
The Face Value of Kwality Pharmaceuticals Ltd is 10.0.